Form 4: Kiniksa COO Sells Shares After Option Exercise

Kiniksa Pharmaceuticals COO Eben Tessari exercised options and subsequently sold a portion of Class A Ordinary Shares under a pre-arranged 10b5-1 plan.

Summary

• Eben Tessari, Chief Operating Officer of Kiniksa Pharmaceuticals International, plc, engaged in transactions involving Class A Ordinary Shares and Share Options on November 17, 2025.
• Tessari exercised 6,500 share options at an exercise price of $8.83 per Class A Ordinary Share.
• Following the exercise, Tessari sold 645 Class A Ordinary Shares at a weighted average price of $40.08, with individual trades ranging from $39.61 to $40.585.
• An additional 11,825 Class A Ordinary Shares were sold at a weighted average price of $41.30, with individual trades ranging from $40.61 to $41.60.
• All reported transactions were executed pursuant to a Rule 10b5-1 plan established by the reporting person on April 29, 2024.
• After these transactions, Tessari's direct beneficial ownership of Class A Ordinary Shares decreased to 22,714 shares.
• Tessari's direct beneficial ownership of derivative securities (share options) is 6,000.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions (option exercise and subsequent share sales) executed under a pre-arranged 10b5-1 plan, which is a neutral event for the company's operational or financial performance.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 plan, indicating planned activity rather than a reaction to immediate, non-public information.
• The sale prices of $40.08 and $41.30 per share are significantly higher than the option exercise price of $8.83, indicating a profitable monetization event for the insider.

Negatives

• Chief Operating Officer Eben Tessari reduced direct beneficial ownership of Class A Ordinary Shares by a net of 12,470 shares following the exercise and sale transactions.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Eben Tessari, Chief Operating Officer of Kiniksa Pharmaceuticals International, plc, exercised stock options and sold Class A Ordinary Shares, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders may observe a reduction in direct insider ownership, though the impact is mitigated by the pre-arranged nature of the transactions under a 10b5-1 plan.

Key Dates

Recommendation

This Form 4 reports a routine, pre-scheduled insider transaction (option exercise and sale) under a 10b5-1 plan. Such transactions are generally not indicative of new material information about the company's prospects and therefore do not warrant a change in investment recommendation based solely on this filing.

Keywords

KNSA, Kiniksa Pharmaceuticals, Eben Tessari, COO, Insider Transaction, Form 4, Stock Options, Share Sale, 10b5-1 Plan